Autophagy in Human Aging: Cell Type– and Sex-Specific Patterns, a Blood Biomarker, and Reversal with Mild Exercise

Table of Contents

1. Key Highlights
2. Introduction
3. Why autophagy matters for aging human cells
4. How the study measured autophagy across cell types and ages
5. Transcriptional changes versus functional autophagy: a striking disconnect
6. Sex- and cell type-specific patterns of autophagy with age
7. Peripheral blood mononuclear cells: a blood-accessible window into cellular aging
8. Exercise, autophagy, and physical function: evidence from a mild intervention
9. Interpreting higher autophagy flux in older, lower-functioning adults
10. Mechanistic hypotheses: why transcriptional upregulation doesn't guarantee increased clearance
11. Practical implications for biomarker development and clinical trials
12. Limitations and open questions
13. Translational pathways: from flux measurement to interventions
14. Real-world examples: how these findings can inform clinical practice and research
15. What clinicians and researchers should watch next
16. FAQ

Key Highlights

• Autophagy-related gene transcription increases with age across human dermal fibroblasts and induced neurons, but functional autophagy (autophagy flux) changes in a cell type- and sex-dependent way and is uncoupled from transcription.
• Higher autophagy flux across examined cell types correlates with poorer physical function in adults aged 70 and older, while a 12-week mild exercise program reduced PBMC autophagy flux and improved physical function.
• Peripheral blood mononuclear cell (PBMC) autophagy flux emerges as a potentially modifiable, blood-accessible indicator of physiological state that could inform geriatric assessment and intervention monitoring.

Introduction

Autophagy—cells’ process for removing and recycling damaged proteins and organelles—features prominently in theories of aging. Long-held assumptions posit a progressive decline in autophagic capacity with age, contributing to the accumulation of cellular damage. Evidence supporting that picture has come largely from model organisms and from isolated tissues, with far less clarity about how autophagy behaves across different human cell types and whether lifestyle interventions that improve function can alter autophagic activity.

A new human cohort study addresses both gaps. Researchers measured transcription of autophagy-related genes and assayed autophagy flux—the dynamic rate of autophagosome formation and clearance—across matched cell types from the same individuals spanning the adult lifespan. The analysis included primary dermal fibroblasts, induced neurons (iNs) derived from those fibroblasts, and freshly isolated peripheral blood mononuclear cells (PBMCs). Results challenge the simple notion of a monotonic decline in autophagy with age. Instead, the study reveals cell type- and sex-specific patterns, a disconnect between gene expression and functional flux, and an association between elevated autophagy flux and reduced physical function in the oldest participants. Importantly, a 12-week mild exercise program lowered autophagy flux while improving physical function, suggesting that autophagy is modifiable and that PBMC flux could serve as a practical biomarker of physiological state in older adults.

The findings recalibrate how autophagy should be considered in geroscience, with direct implications for biomarker development, clinical trials, and design of lifestyle or pharmacologic interventions aimed at preserving function with age.

Why autophagy matters for aging human cells

Cells rely on autophagy to maintain protein quality control, eliminate dysfunctional organelles, and supply substrates for metabolism under stress. When autophagy functions appropriately, cellular homeostasis is preserved; when it fails or becomes dysregulated, damaged components accumulate and cellular function declines.

Aging is characterized by diminished proteostasis, mitochondrial dysfunction, and increased oxidative stress—phenotypes autophagy mechanistically counters. Experimental models show that enhancing autophagy can extend lifespan or delay age-related phenotypes, while genetic or pharmacologic impairment accelerates decline. Translating these insights to humans requires two types of knowledge: how autophagy behaves in diverse human cell types across age, and whether autophagy responds to interventions that alter physiological health.

The new study provides direct human data on both points. It profiles transcriptional shifts in autophagy-related genes and measures autophagy flux—a functional readout that captures the throughput of the entire autophagic pathway—in three cell compartments accessible from living individuals. That approach addresses a central problem: gene expression does not always predict protein activity or pathway throughput. Only by measuring dynamics can researchers know whether autophagy is effectively operating to clear cargo.

Understanding these dynamics becomes particularly important when considering clinical translation. For an intervention—whether exercise, dietary change, or a drug aimed at modulating autophagy—to be judged effective, researchers need reliable, accessible biomarkers that reflect meaningful changes in cellular maintenance and correlate with organismal outcomes such as strength, mobility, or frailty. The work under discussion establishes the groundwork for such biomarkers.

How the study measured autophagy across cell types and ages

The approach combined transcriptomics and functional assays applied to subject-matched cells across the adult lifespan. Primary dermal fibroblasts were obtained from skin biopsies and maintained in culture. A subset of those fibroblasts was directly converted into induced neurons (iNs) using established reprogramming approaches that preserve many age-associated features while enabling neuronal phenotyping. Freshly isolated PBMCs were used to capture a blood-accessible signal reflecting immune and systemic states.

RNA sequencing compared expression of established autophagy-related genes across fibroblasts and iNs from donors spanning young to old adulthood. Functional autophagy flux assays measured the dynamic activity of the autophagy pathway in all three cell types. Autophagy flux estimates the balance between formation of autophagosomes and their clearance by lysosomes; a snapshot of autophagy without considering flux can be misleading because static accumulation of autophagosomes may reflect either increased production or impaired clearance.

By examining matched cell types from the same individuals, the investigators controlled for inter-subject variability in systemic factors and genetic background, permitting clearer attribution of observed differences to cell type, sex, and age. The cohort also included an intervention: older participants engaged in a 12-week mild exercise program, enabling pre- and post-intervention comparisons of autophagy flux and physical function.

This multi-pronged, within-subject design gives weight to the conclusions. It avoids many pitfalls of cross-sectional studies that compare disparate cohorts and offers one of the first direct human demonstrations that autophagy’s behavior with age is neither uniform across cell types nor reducible to changes in gene transcription alone.

Transcriptional changes versus functional autophagy: a striking disconnect

Transcriptomic profiling showed widespread upregulation of autophagy-related genes with age, most markedly in dermal fibroblasts. Genes involved in autophagosome formation, lysosomal function, and related pathways exhibited increased mRNA levels in older donors. That pattern suggests a cell-intrinsic transcriptional response with age that could reflect compensatory upregulation in the face of accumulating damage.

Functional assays told a different story. Autophagy flux did not follow the transcriptional trend in a straightforward way. Instead, flux changed in a cell type- and sex-dependent manner and in some instances moved opposite to what gene expression might predict. Male fibroblasts showed a decline in autophagy flux with age. Female fibroblasts did not show age-related change in flux despite increased autophagy-gene transcription. Female iNs exhibited an age-associated increase in autophagy flux. PBMC flux became more heterogeneous with age and trended higher in older individuals, irrespective of sex.

This uncoupling between transcription and flux highlights important biological principles. First, mRNA abundance is an imperfect proxy for protein-level function, especially for multi-step processes like autophagy that are regulated at translational, post-translational, and organelle-functional levels. Second, different cellular compartments may face distinct stressors and regulatory environments: what drives the transcriptional program in fibroblasts may not determine functional activity inside neurons or immune cells. Third, clearance capacity—principally lysosomal function—can limit autophagy flux independently of gene expression for upstream autophagy machinery.

The human data emphasize that assessing autophagy for diagnostic or interventional purposes requires measuring the pathway’s throughput rather than relying on gene-expression surrogates alone. This point has immediate implications for biomarker development and for interpreting studies that use transcriptomic or proteomic signatures to infer autophagy activity.

Sex- and cell type-specific patterns of autophagy with age

The study’s stratified analysis by sex revealed divergent aging trajectories for autophagy flux in fibroblasts and neurons. Male fibroblasts displayed a clear reduction in autophagy flux with age. Female fibroblasts maintained relatively stable flux across ages. Induced neurons derived from older female donors showed increased autophagy flux, while corresponding male iNs did not present the same pattern.

Sex differences in autophagy regulation have precedent in the literature, though direct human cellular data across age have been scarce. Sex hormones—estrogens, androgens, and their downstream signaling pathways—modulate autophagy in tissue-specific ways. Genetic and epigenetic factors, immune system differences, and distinct patterns of age-related comorbidities between men and women can also shape cellular stress responses.

Cell type further influences the aging pattern. Dermal fibroblasts and neurons have distinct roles, proteostatic demands, and exposure histories. Fibroblasts are proliferative, engaged in extracellular matrix maintenance and wound repair; neurons are post-mitotic, long-lived, and highly reliant on autophagy for turnover of organelles like mitochondria. The observation that female iNs exhibit increased flux with age could reflect an adaptive response to accumulate damage over decades of post-mitotic life, whereas male fibroblasts’ decreased flux might indicate declining clearance capacity in proliferative somatic cells.

PBMCs behaved differently: flux became more heterogeneous with age and trended higher in older individuals regardless of sex. Immune cell populations shift composition with aging—changes in proportions of T cells, B cells, monocytes, and natural killer cells occur—potentially contributing to the observed heterogeneity. Furthermore, systemic inflammation that often increases with age could stimulate autophagy in immune cells as part of a stress-response program.

These sex- and cell-specific patterns caution against sweeping generalizations about autophagy in aging. Any therapeutic strategy targeting autophagy will need to account for these nuances, both to maximize benefit and to avoid unintended consequences in tissues where autophagy is already elevated or otherwise dysregulated.

Peripheral blood mononuclear cells: a blood-accessible window into cellular aging

PBMCs offered a practical advantage: they are readily obtainable from routine blood draws, enabling repeated measurements in clinical settings. The study found that autophagy flux in PBMCs becomes more variable with age and tends to be higher in older individuals. This variability likely reflects heterogeneity in immune cell composition, varying disease burden, medication exposures, and lifestyle factors among older adults.

Most importantly, PBMC autophagy flux correlated with physical function: across the examined cell types, higher autophagy flux was associated with reduced physical function in adults 70 years and older. That association suggests PBMC flux may capture a systemic physiological state linked with frailty or declining functional reserve.

A blood-based readout that correlates with clinically meaningful outcomes offers major advantages. It could serve as a minimally invasive biomarker to:

• Screen older adults for physiological decline or elevated cellular stress.
• Stratify participants in clinical trials targeting aging pathways.
• Monitor response to interventions such as exercise programs, dietary changes, or autophagy-modulating drugs.

The study shows PBMC flux is modifiable by lifestyle intervention, reinforcing its potential utility. PBMC measures will need validation in larger, diverse cohorts and in longitudinal designs, but the concept of using immune-cell autophagy as a sentinel of organismal health is compelling.

Exercise, autophagy, and physical function: evidence from a mild intervention

A critical, actionable component of the study was the 12-week mild exercise intervention administered to older participants. After the program, participants showed improved physical function and a decrease in measured autophagy flux. The simultaneous improvement in function and reduction in autophagy flux suggests that elevated autophagy flux in older adults may reflect a compensatory response to cellular stress rather than a beneficial upregulation of maintenance activity.

Exercise is known to affect multiple cellular pathways: it improves mitochondrial function, enhances insulin sensitivity, reduces systemic inflammation, and promotes proteostasis. By alleviating upstream stressors—damaged proteins, dysfunctional mitochondria, oxidative stress—exercise may reduce the need for high autophagic throughput. Observing decreased PBMC autophagy flux after mild exercise supports the interpretation that flux can be responsive to improved physiological state, not merely a marker of chronological age.

This pattern has practical implications. Clinicians and researchers often regard increases in autophagy as adaptive and desirable. However, when increased flux occurs in the context of poor function, it may be a biomarker of ongoing cellular challenge rather than effective clearance. Interventions that lower autophagy flux while improving organismal function could thus indicate improved cellular homeostasis rather than inhibition of a protective process.

Translating this to community practice: a mild, structured exercise program—consistent with many public health recommendations for older adults—may produce measurable changes in blood-cell autophagy within months. That finding opens the door to incorporating autophagy flux monitoring into intervention studies assessing exercise or rehabilitation, potentially enabling dose optimization and personalization.

Interpreting higher autophagy flux in older, lower-functioning adults

The association of elevated autophagy flux with reduced physical function in older adults requires careful interpretation. Several non-exclusive models can explain the pattern.

1. Compensatory activation model: Chronic accumulation of damaged proteins, impaired mitochondria, or inflammatory signals increases autophagy initiation. Flux may be elevated because upstream sensors stimulate the pathway to clear accumulating cargo. If degradation machinery (lysosomes) keeps pace, flux could represent effective maintenance. But if lysosomal function is impaired, accumulation can persist despite increased initiation.
2. Incomplete clearance model: Increased flux measurements may reflect stalled clearance where autophagosomes accumulate due to lysosomal dysfunction. Depending on the assay, increased autophagosome markers could be interpreted as higher flux, when they reflect bottlenecks. The study addressed this by employing flux-specific assays, which better distinguish increased throughput from static accumulation; nonetheless, cellular heterogeneity complicates interpretation.
3. Stress-response marker: Elevated autophagy flux in PBMCs could be a systemic indicator of sustained physiologic stress in older adults—driven by comorbidities, infection history, inflammation, or metabolic dysfunction—rather than a primary driver of poor function.
4. Adaptive yet insufficient response: Autophagy may be upregulated in response to stress, but the magnitude or quality of the response might be inadequate to restore homeostasis. Thus, higher flux coexists with ongoing dysfunction.

The key clinical takeaway is that context matters. Elevated autophagy flux is not universally beneficial or harmful. When accompanied by declining physical performance, it may signal that cells are straining to cope with damage. Conversely, in different contexts—such as acute exercise-induced autophagy in healthy individuals—increases might mediate beneficial remodeling.

Longitudinal monitoring can help distinguish transient adaptive increases from chronic, maladaptive activation. The observed decline in flux after exercise concomitant with functional gains suggests that at least some instances of elevated flux in older adults mark reversible stress states rather than irreversible cellular failure.

Mechanistic hypotheses: why transcriptional upregulation doesn't guarantee increased clearance

The disconnect between increased autophagy-gene transcription and functional flux in specific cell types points to regulatory checkpoints beyond mRNA abundance. Several mechanisms could account for this dissociation.

• Post-transcriptional control: mRNA may not be efficiently translated into functional protein. MicroRNAs, RNA-binding proteins, and translational machinery decline with age in tissue-specific ways.
• Post-translational modifications: Autophagy proteins require precise phosphorylation, ubiquitination, and lipidation to function. Dysregulation of kinases and phosphatases with age could impair activation.
• Organelle dysfunction: Lysosomal acidity and enzyme activity decline in some aging contexts. Even with intact autophagosome formation, impaired lysosomal degradation will limit throughput.
• Energy and metabolic state: Autophagy is energy-dependent. Cellular ATP deficits or altered nutrient-sensing pathways can shift autophagic dynamics independent of gene expression.
• Compartmental specificity: Neurons and fibroblasts differ in organelle architecture and trafficking. Proteostatic demands and capacity for autophagosome transport to lysosomes vary, altering effective flux.
• Immune and inflammatory signaling: Cytokines and immune mediators shape autophagy activation and resolution. Age-related chronic inflammation might sustain autophagy signaling in immune cells without matching capacity for effective degradation.

These mechanisms are not mutually exclusive. Dissecting them will require integrated measurement: transcriptomics combined with proteomics, lysosomal functional assays, imaging of autophagosome–lysosome dynamics, and metabolic profiling across cell types and sexes.

Practical implications for biomarker development and clinical trials

The study provides a roadmap for applying autophagy measures in translational and clinical settings.

• PBMC autophagy flux as a biomarker: PBMCs are obtainable in routine clinical contexts, and their flux correlates with physical function in older adults. This makes them attractive as a minimally invasive biomarker for geriatric assessments or for stratifying participants in trials of geroprotective therapies.
• Monitoring intervention response: Exercise reduced PBMC flux while improving function. Trials of lifestyle, pharmacologic, or nutraceutical interventions could use PBMC flux to monitor biological response, complementing functional endpoints.
• Tissue-specific considerations: Autophagy modulation efforts must recognize cell-type specificity. A systemic autophagy activator may benefit tissues with declining flux but risk harm where flux is already high or where lysosomal function is impaired.
• Sex-specific strategies: The observed sex differences argue for sex-stratified analyses in trials. Dosing, timing, or combination therapies might require tailoring by sex to achieve optimal outcomes.
• Multi-parameter panels: Relying on a single measure risks misinterpretation. Combining PBMC flux with markers of lysosomal function, inflammatory status, and functional performance will yield a more robust picture of an individual’s cellular health.
• Regulatory and logistical considerations: Standardizing flux assays for clinical use will require reproducible protocols, robust reference ranges across ages and sexes, and understanding of confounders such as recent infections, medications (e.g., immunomodulators), and acute physical activity.

Implementing autophagy flux measurement in clinical trials would benefit from a phased approach: confirmatory studies in larger cohorts, assay harmonization across labs, and integration into randomized trials to test whether changes in flux predict meaningful clinical benefits.

Limitations and open questions

The study advances understanding but leaves critical questions.

• Cohort size and diversity: The findings come from a well-characterized cohort, but broader validation across more diverse populations—different ethnic groups, comorbidity profiles, and geographic settings—is necessary.
• Cross-sectional versus longitudinal evidence: Much of the age-related analysis is cross-sectional, which cannot fully disentangle cohort effects from true aging trajectories. Longitudinal follow-up would strengthen causal inference about how autophagy changes within individuals over time.
• Nature of induced neurons: iNs retain many age-associated signatures but are not identical to in vivo neurons. How well iN flux reflects neuronal autophagy in brain tissue remains an open question.
• Mechanistic detail: The study documents patterns; mechanistic dissection of why transcriptional upregulation fails to translate into increased flux in some contexts remains to be completed. Direct measures of lysosomal function, post-translational modification states of key autophagy proteins, and proteostasis burden are needed.
• Assay specificity: While autophagy flux assays are more informative than static measures, they have limitations. Assays must be interpreted in light of cell viability, metabolic state, and composition of cell populations (particularly relevant for PBMCs).
• Clinical thresholds: The study links higher flux to poorer function but does not define actionable clinical thresholds. Future work must determine what magnitude of flux change predicts clinically meaningful outcomes and over what timeframe.
• Effects of specific exercise regimens: The 12-week mild exercise program produced favorable changes, but the optimal type, intensity, and duration of exercise for modulating autophagy remain to be defined.

Answering these questions will take coordinated efforts across basic, translational, and clinical research.

Translational pathways: from flux measurement to interventions

The study opens multiple translational pathways.

1. Diagnostic tools: Develop standardized PBMC autophagy flux assays for use in geriatric clinics to detect early physiological decline and to personalize intervention plans.
2. Intervention monitoring: Incorporate PBMC flux into clinical trials of exercise, nutritional strategies (e.g., protein timing, caloric modulation), and pharmacologic agents that target autophagy or lysosomal function.
3. Target discovery: Use matched-cell-type profiling to identify molecular bottlenecks (e.g., lysosomal acidification deficits, defective lysosomal enzymes) that could be targeted therapeutically. An agent that restores lysosomal function could convert transcriptional upregulation into effective clearance.
4. Sex-informed therapies: Design trials that examine sex-specific responses to autophagy-modulating treatments and evaluate whether sex-based stratification improves outcomes.
5. Multi-modal programs: Combine exercise with targeted pharmacologic or dietary interventions, using PBMC flux and physical function as readouts to optimize combined regimens.

For each path, careful consideration of safety is crucial. Autophagy modulation can have complex effects: enhancing clearance may reduce aggregate burden in neurodegeneration, but excessive induction or inappropriate activation could perturb cell survival pathways in other contexts. Rigorous preclinical and early-phase clinical testing must proceed alongside biomarker development.

Real-world examples: how these findings can inform clinical practice and research

Several illustrative scenarios show how autophagy flux measurement and its responsiveness to exercise could be used in practice.

• Rehabilitation after hospitalization: Older adults often lose mobility after hospitalization. Measuring PBMC autophagy flux at hospital discharge and after a structured rehabilitation program could help assess biological recovery. A decline in flux alongside improved gait speed or chair-stand performance would suggest restored cellular homeostasis.
• Preclinical screening in trials for neurodegenerative disease: Trials testing drugs that aim to clear pathological protein aggregates might use PBMC flux as a peripheral pharmacodynamic marker. If a drug meaningfully enhances lysosomal degradation, PBMC flux might shift towards patterns associated with improved function.
• Personalized exercise prescriptions: Older adults with elevated PBMC flux and lower baseline function might be prioritized for structured exercise programs. Tracking flux could help tailor intensity and duration, increasing adherence and efficiency in community-based programs.
• Monitoring polypharmacy effects: Certain medications influence autophagy. PBMC flux measurements could alert clinicians to drug-induced disruptions in cellular clearance pathways, prompting medication review in frail older adults.

These examples illustrate feasible applications that lever the accessibility of PBMCs and the responsiveness of autophagy flux to interventions.

What clinicians and researchers should watch next

Immediate priorities include:

• Replication in larger, more diverse cohorts with longitudinal follow-up to clarify trajectories and causality.
• Standardization of autophagy flux assays and generation of age- and sex-specific reference ranges.
• Parallel measurement of lysosomal function and proteostatic burden to dissect mechanistic drivers of flux changes.
• Comparative studies examining different exercise intensities, durations, and modalities to define optimal regimens for modulating autophagy and improving function.
• Integration of flux measures into randomized controlled trials testing pharmacologic autophagy modulators or combination lifestyle-pharmacologic approaches.

Success in these areas will determine whether PBMC autophagy flux becomes a routine biomarker in geriatric assessment and therapeutic monitoring.

FAQ

Q: What is autophagy flux, and how does it differ from measuring autophagy-related gene expression? A: Autophagy flux quantifies the dynamic process of autophagosome formation and their degradation by lysosomes. It captures throughput—the effective clearance of cellular cargo—rather than static abundance of autophagy structures. Gene expression measures mRNA levels for autophagy-related proteins and does not necessarily reflect protein activity, post-translational regulation, or lysosomal capacity. The study shows gene transcription can rise with age while functional flux shows distinct, cell type- and sex-dependent patterns.

Q: Why might increased autophagy flux be associated with worse physical function in older adults? A: Elevated autophagy flux in older adults may indicate ongoing cellular stress and a compensatory attempt to clear accumulated damage. It does not automatically mean effective maintenance. If autophagy is upregulated because of persistent damage or inflammation, higher flux can coexist with impaired cellular and organismal function. The observed reduction in flux after exercise alongside functional improvement supports the interpretation that high flux can be a marker of stress rather than benefit.

Q: Can measuring autophagy flux in blood cells really tell us what’s happening in tissues like muscle or brain? A: PBMCs provide a peripheral, accessible readout that reflects systemic physiological state. While they do not directly measure autophagy in muscle or brain, their flux correlated with physical function in older adults in this study, suggesting they capture relevant systemic signals. Correlations do not imply equivalence; tissue-specific assessment remains necessary for precise mechanistic insight. PBMC flux is most useful as a practical biomarker of organismal health and response to interventions.

Q: Does exercise increase or decrease autophagy? A: Exercise can acutely stimulate autophagy in multiple tissues as part of adaptive remodeling. Over longer intervals, exercise improves mitochondrial function and reduces systemic stressors, which may lower the need for sustained autophagic activation. In the cited study, a 12-week program of mild exercise decreased PBMC autophagy flux while improving physical function, indicating that chronic improvements in physiology can reduce baseline autophagic demand.

Q: Are there sex-specific recommendations based on these findings? A: The study found sex differences in age-related autophagy flux patterns, implying potential value in sex-stratified analyses in research and perhaps in clinical decision-making. However, evidence is not yet sufficient to recommend different clinical interventions by sex solely on autophagy measures. Future trials should examine sex-specific responses to therapies targeting autophagy to inform tailored recommendations.

Q: How close are we to using autophagy flux as a clinical biomarker? A: The concept shows promise. PBMC autophagy flux is accessible, correlates with function, and responds to intervention. Before clinical adoption, flux assays need standardization, validation across diverse cohorts, and demonstration that changes predict clinically important outcomes. Ongoing research should address these steps.

Q: What are the main limitations of the study? A: Limitations include the need for replication in larger and more diverse cohorts, the cross-sectional nature of much of the age analysis, and reliance on induced neurons that, while age-retaining, are not identical to in vivo neurons. Assay-specific constraints and heterogeneity among PBMC subpopulations also warrant further scrutiny.

Q: What should researchers do next to build on these results? A: Priorities include longitudinal cohort studies, mechanistic investigations into lysosomal function and post-translational regulation, assay harmonization, and incorporation of PBMC flux into randomized trials of lifestyle and pharmacologic interventions. Sex- and tissue-specific effects deserve focused exploration.

Q: Could drugs that modulate autophagy reverse age-related functional decline? A: Preclinical data in model organisms suggest autophagy modulation can influence aging phenotypes. Translating that to humans requires careful testing. Drugs that enhance autophagic clearance or restore lysosomal function may benefit tissues where clearance is impaired, but systemic modulation poses risks if applied without tissue and sex specificity. Clinical trials incorporating validated biomarkers like PBMC flux could help define therapeutic windows and safety.

Q: If I am an older adult, should I change my behavior based on this study? A: The study reinforces existing evidence that structured mild exercise can improve physical function in older adults and that such improvements may accompany measurable biological changes indicative of reduced cellular stress. Decisions about initiation or modification of exercise programs should be made with healthcare providers, considering individual health status. The findings support mild exercise as a practical intervention with both functional and cellular benefits.